Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Bing Z. Carter(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Duncan H. Mak(The University of Texas MD Anderson Cancer Center), Hong Mu(Tianjin First Center Hospital), Wendy Schober(The University of Texas MD Anderson Cancer Center), Hongsheng Zhou(Ganzhou People's Hospital), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Po Yee Mak(The University of Texas MD Anderson Cancer Center), Joel D. Leverson(AbbVie (United States)), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Ravi Bhatia(University of Alabama at Birmingham), Bin Zhang(City Of Hope National Medical Center), Jörge E. Cortes(Augusta University Health)
Cited by 172
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k